scholarly journals In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

10.3791/2125 ◽  
2010 ◽  
Author(s):  
Alexis B. Cordero ◽  
Youngjoo Kwon ◽  
Xiang Hua ◽  
Andrew K. Godwin
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Orthotopic Mouse Model

scholarly journals A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Mitchell Clark ◽  
Alexandra Kollara ◽  
Theodore J. Brown ◽  
Taymaa May
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mouse Model ◽  
Cytoreductive Surgery ◽  
Residual Disease ◽  
Accelerated Expansion ◽  
Ovarian Cancer Cells ◽  
Orthotopic Mouse Model ◽  
The Impact

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.

scholarly journals A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

2021 ◽  
Author(s):  
Mitchell Clark ◽  
Alexandra Kollara ◽  
Theodore Brown ◽  
Taymaa May
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mouse Model ◽  
Cytoreductive Surgery ◽  
Residual Disease ◽  
Accelerated Expansion ◽  
Ovarian Cancer Cells ◽  
Orthotopic Mouse Model ◽  
The Impact

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.

scholarly journals Characterization of Lung Cancer by Amide Proton Transfer (APT) Imaging: An In-Vivo Study in an Orthotopic Mouse Model

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77019 ◽  
Author(s):  
Osamu Togao ◽  
Chase W. Kessinger ◽  
Gang Huang ◽  
Todd C. Soesbe ◽  
Koji Sagiyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mouse Model ◽  
Proton Transfer ◽  
In Vivo Study ◽  
Amide Proton ◽  
Orthotopic Mouse Model ◽  
Amide Proton Transfer ◽  
Apt Imaging

An Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis

10.3791/62382 ◽  
2021 ◽  
Author(s):  
Huda I. Atiya ◽  
Taylor J. Orellana ◽  
Alyssa Wield ◽  
Leonard Frisbie ◽  
Lan G. Coffman
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Orthotopic Mouse Model

scholarly journals In vivo optical coherence tomography of a mouse model of spontaneous ovarian cancer

2019 ◽  
Author(s):  
Travis W. Sawyer ◽  
Jennifer Watson-Koevary ◽  
Photini F. S. Rice ◽  
Jennifer K. Barton
Keyword(s):  
Ovarian Cancer ◽  
Optical Coherence Tomography ◽  
Mouse Model ◽  
Optical Coherence

scholarly journals An Immunocompetent, Orthotopic Mouse Model of Epithelial Ovarian Cancer Utilizing Tissue Engineered Tumor Cell Sheets

2015 ◽  
Vol 21 (1) ◽  
pp. 23-34 ◽  
Author(s):  
Ayumi Arauchi ◽  
Chieh-Hsiang Yang ◽  
Sungpil Cho ◽  
Elke A. Jarboe ◽  
C. Matthew Peterson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Tumor Cell ◽  
Epithelial Ovarian Cancer ◽  
Cell Sheets ◽  
Orthotopic Mouse Model

scholarly journals In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

2011 ◽  
Vol 10 (8) ◽  
pp. 1440-1449 ◽  
Author(s):  
Kathryn M. Kinross ◽  
Daniel V. Brown ◽  
Margarete Kleinschmidt ◽  
Susan Jackson ◽  
James Christensen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Mek Inhibition ◽  
Pten Deletion

scholarly journals Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer

2014 ◽  
Vol 25 (2) ◽  
pp. 130 ◽  
Author(s):  
Ho-Suap Hahn ◽  
Ki-Heon Lee ◽  
In-Ho Lee ◽  
Jae-Ho Lee ◽  
Chang-Sung Whang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Orthotopic Mouse Model ◽  
Oral Paclitaxel

scholarly journals Thyroxine promotes lung cancer growth in an orthotopic mouse model

2019 ◽  
Vol 26 (6) ◽  
pp. 565-574 ◽  
Author(s):  
S Latteyer ◽  
S Christoph ◽  
S Theurer ◽  
G S Hönes ◽  
K W Schmid ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Plasma Membrane ◽  
Thyroid Hormone ◽  
Mouse Model ◽  
Tumor Growth ◽  
Hormone Receptors ◽  
Cancer Growth ◽  
Orthotopic Mouse Model ◽  
Tumor Weight

Thyroid hormones are important for physiology and homeostasis. In addition to nuclear thyroid hormone receptors, the plasma membrane protein integrin αvβ3 has been recognized as a receptor for both thyroxine (T4) and triiodothyronine (T3). Here, we studied whether thyroid hormone promotes growth of murine lung cancer via αvβ3 in vivo. Murine Lewis lung carcinoma cells (3LL), stably transfected with luciferase, were injected into mouse lungs. Tumor growth in untreated mice was compared to hypothyroid mice and hypothyroid mice treated with T3 or T4 with or without the αvβ3 inhibitor 3,5,3′,5′-tetraiodothyroacetic acid (Tetrac). Tumor progression was determined by serial in vivo imaging of bioluminescence emitted from the tumor. Tumor weight was recorded at the end of the experiment. Neoangiogenesis was determined by immunohistochemistry for CD31. Tumor growth was reduced in hypothyroidism and increased by T4 treatment. Strikingly, only T4 but not T3 treatment promoted tumor growth. This T4 effect was abrogated by the αvβ3 inhibitor Tetrac. Tumor weight and neoangiogenesis were also significantly increased only in T4-treated mice. The T4 effect on tumor weight and neoangiogenesis was abolished by Tetrac. In vitro, T4 did not stimulate 3LL cell proliferation or signaling pathway activation. We conclude that T4 promotes lung cancer growth in this orthotopic mouse model. The tumor-promoting effect is mediated via the plasma membrane integrin αvβ3 and increased neoangiogenesis rather than direct stimulation of 3LL cells. These data suggest that such effects of levothyroxine may need to be considered in cancer patients on T4 substitution.

Sign in / Sign up

Export Citation Format

Share Document